Nathan Yates, PhD

Associate Professor, Department of Cell Biology

Nathan Yates, PhD

yatesn@pitt.edu

Office:
Phone: 732-718-9739
Fax:

Department of Cell Biology

Biosketch

Allegheny College, Meadville, PA BS 06/1988 Chemistry
University of Florida, Gainesville, FL PHD 05/1993 Analytical Chemistry
University of Virginia, Charlottesville, VA Postdoctoral Fellow 11/1995 Bio-analytical Chemistry

My 25 plus years of experience with mass spectrometry have afforded me numerous opportunities to advance academic, government, and industrial science through the development and application of new molecular analysis methods. Advances in mass spectrometry are inextricably linked to the rapid growth in scientific discoveries and data. The ultimate goal of my work is to bring these new experimental innovations to the broader scientific community. As an industrial and academic scientists, I have led collaborative efforts to design new instrumentation and data analysis tools that impact important areas of science. At Merck and Co. Inc., my work centered on the development new medicines, the discovery of protein biomarkers, and the translation of diagnostic assays to the clinic. My academic research program at the University of Pittsburgh is highly collaborative and interdisciplinary, bringing together experts in protein biochemistry, mass spectrometry, and informatics. As the Director of a campus-wide center for mass spectrometry, I have the opportunity to collaborate with investigators whose research programs span from understanding basic biology to developing new therapies and approaches for treating disease.

  1. Threonine 89 Is an Important Residue of Profilin-1 That Is Phosphorylatable by Protein Kinase A. Gau D, Veon W, Zeng X, Yates N, Shroff SG, Koes DR, Roy P. PLoS One. 2016 May 26;11(5):e0156313. doi: 10.1371/journal.pone.0156313. eCollection 2016. PMID: 27228149
  2. Abnormal lipid processing but normal long-term repopulation potential of myc-/- hepatocytes. Edmunds LR, Otero PA, Sharma L, D'Souza S, Dolezal JM, David S, Lu J, Lamm L, Basantani M, Zhang P, Sipula IJ, Li L, Zeng X, Ding Y, Ding F, Beck ME, Vockley J, Monga SP, Kershaw EE, O'Doherty RM, Kratz LE, Yates NA, Goetzman EP, Scott D, Duncan AW, Prochownik EV. Oncotarget. 2016 Apr 20. doi: 10.18632/oncotarget.8856. [Epub ahead of print] PMID: 27105497
  3. Apolipoprotein E*4 (APOE*4) Genotype Is Associated with Altered Levels of Glutamate Signaling Proteins and Synaptic Coexpression Networks in the Prefrontal Cortex in Mild to Moderate Alzheimer Disease. Sweet RA, MacDonald ML, Kirkwood CM, Ding Y, Schempf T, Jones-Laughner J, Kofler J, Ikonomovic MD, Lopez OL, Garver ME, Fitz NF, Koldamova R, Yates NA. Mol Cell Proteomics. 2016 Jul;15(7):2252-62. doi: 10.1074/mcp.M115.056580. Epub 2016 Apr 21. PMID: 27103636
  4. Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration. Kirkwood CM, MacDonald ML, Schempf TA, Vatsavayi AV, Ikonomovic MD, Koppel JL, Ding Y, Sun M, Kofler JK, Lopez OL, Yates NA, Sweet RA. J Neuropathol Exp Neurol. 2016 Feb;75(2):175-82. PMID: 26769253
  5. Clinical and Pharmaceutical Solutions through Analysis (CPSA BRASIL 2015): on the way to innovation - pharmaceutical/analytical technology, regulation and knowledge management. Needham S, Yates N, Barrientos R, Steel M, Lee M. Bioanalysis. 2015 Dec;7(23):2977-9. doi: 10.4155/bio.15.216. Epub 2015 Nov 30. PMID: 26617112